S&P 500
5.222,68 +94,89 (+1,85%) Nasdaq
16.340,87 +184,57 (+1,14%) NIKKEI 225
38.224,64 -4,47 (-0,01%) Dólar/Euro
1,0775 +0,0002 (+0,02%) Petróleo Brent
82,54 -0,25 (-0,30%) Bitcoin EUR
56.720,63 +169,24 (+0,30%)
Notable Labs, Ltd. (NTBL)
Después del cierre:
Notable Labs, Ltd.
320 Hatch Drive
Foster City, CA 94404
United States
415-851-2410
https://www.notablelabs.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 16
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Thomas A. Bock M.B.A., M.D. | CEO & Director | 508,82k | N/A | 1965 |
| Mr. Scott Alan McPherson CFE, CPA, CVA | Chief Financial Officer | 412,89k | N/A | 1961 |
| Dr. Joseph P. Wagner Ph.D. | Chief Scientific Officer | 424,88k | N/A | 1968 |
| Dr. Glenn C. Michelson M.D. | Chief Medical Officer | N/A | N/A | N/A |
Descripción
Notable Labs, Ltd., a clinical-stage platform therapeutics company, engages in developing predictive precision medicines for patients with cancer. The company, through its proprietary Predictive Precision Medicines Platform (PPMP), bio-simulates a cancer treatment and predicts, whether or not the patient will clinically respond to their actual treatment. Its PPMP is designed to identify and select clinically responsive patients prior to their treatment and thus fast-track therapeutic development in this patient population. The company's pipeline includes Volasertib, a potent Polo-like kinase 1 (PLK-1) inhibitor to induce cell cycle arrest and apoptosis in various cancer cells.; and Fosciclopirox, a pro-drug of ciclopirox for AML. Notable Labs, Ltd. was incorporated in 2014 and is headquartered in Foster City, California.
Gobierno corporativo
El ISS Governance QualityScore de Notable Labs, Ltd., a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.
